Pabst, T. Et Al. 2023. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. The Lancet Haematology , vol.10, no.11 .

Pabst, T., Papayannidis, C., DEMİRKAN, F., Doronin, V., Fogliatto, L. M., Guttke, C., ... Gyan, E.(2023). Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. The Lancet Haematology , vol.10, no.11.

Pabst, Thomas Et Al. "Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study," The Lancet Haematology , vol.10, no.11, 2023

Pabst, Thomas Et Al. "Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study." The Lancet Haematology , vol.10, no.11, 2023

Pabst, T. Et Al. (2023) . "Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study." The Lancet Haematology , vol.10, no.11.

@article{article, author={Thomas Pabst Et Al. }, title={Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study}, journal={The Lancet Haematology}, year=2023}